Choroidal Neovascularization - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Choroidal Neovascularization - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 91-page report is available in PDF from $2000.

Choroidal Neovascularization - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Choroidal Neovascularization - Pipeline Review, H1 2015’, provides an overview of the Choroidal Neovascularization’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Choroidal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Choroidal Neovascularization and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Choroidal Neovascularization pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Choroidal Neovascularization Overview 8
Therapeutics Development 9
Pipeline Products for Choroidal Neovascularization - Overview 9
Pipeline Products for Choroidal Neovascularization - Comparative Analysis 10
Choroidal Neovascularization - Therapeutics under Development by Companies 11
Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes 12
Choroidal Neovascularization - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Choroidal Neovascularization - Products under Development by Companies 16
Choroidal Neovascularization - Products under Investigation by Universities/Institutes 17
Choroidal Neovascularization - Companies Involved in Therapeutics Development 18
Affitech A/S 18
F. Hoffmann-La Roche Ltd. 19
Genentech, Inc. 20
Iconic Therapeutics, Inc. 21
Navigen Pharmaceuticals, Inc. 22
Promedior, Inc. 23
Regeneron Pharmaceuticals, Inc. 24
Resolvyx Pharmaceuticals, Inc 25
Sanwa Kagaku Kenkyusho Co., Ltd. 26
Valens Therapeutics, Inc. 27
Choroidal Neovascularization - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
aflibercept (recombinant) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antisense Oligonucleotides to Inhibit VEGFR-1 and VEGFR-2 for Ophthalmology and Cancer - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
doxorubicin pegylated nanoparticle - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
hI-con1 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MAb-30D8 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NAV-2729 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Netrin-4 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PGN-635 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PRM-167 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ranibizumab - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Protein for Choroidal Neovascularization - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
RX-20001 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SK-1011 - Drug Profile 58
Product Description…

For more information open Choroidal Neovascularization - Pipeline Review, H1 2015.


Original Article: Choroidal Neovascularization - Pipeline Review, H1 2015


More From BioPortfolio on "Choroidal Neovascularization - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...